Semaglutide Loss of Exclusivity and What It Could Mean for Weight Treatment

How patent exclusivity actually works for a medicine like semaglutide

When a pharmaceutical company develops a new medicine, it files patents covering the molecule itself, the way it is formulated, the device used to deliver it, and sometimes the manufacturing process. Novo Nordisk, which makes Wegovy and Ozempic, holds a portfolio of patents around semaglutide that do not all expire on the same date, and if you want to understand more about the company behind these medicines, our page on the Wegovy parent company covers its structure and history in more detail. This layered protection is standard practice for complex medicines and means that 'loss of exclusivity' is rarely the single event it sounds like.

The primary composition-of-matter patents for semaglutide are widely expected to begin expiring in the mid-2020s in some markets, though the exact position in the UK can differ from the US or EU because national patent extensions and supplementary protection certificates (SPCs) vary by jurisdiction. Regulatory exclusivity (a separate protection granted by the MHRA when a medicine is authorised) adds further time before a competitor can rely on Novo Nordisk's clinical data to support its own application. These two protections run in parallel, which is why analysts tracking semaglutide loss of exclusivity often quote a range of years rather than a single date.

For readers on Wegovy, the practical upshot is that the window before a licensed semaglutide alternative appears in the UK pharmacy supply chain is still measured in years, not months. Our overview of semaglutide covers the medicine's mechanism and current licensed status in the UK if you want the clinical background alongside the commercial picture.

What biosimilar approval would involve, and why it takes longer for injectables

Once patent and exclusivity protections fall away, a rival manufacturer can apply to the MHRA for approval of a biosimilar or generic version. For small-molecule tablets, this is a well-worn path: a generic manufacturer demonstrates that its product is bioequivalent and receives approval relatively quickly. Semaglutide is different. It is a large peptide molecule synthesised through a complex biological process, which makes it more akin to a biologic than a conventional small-molecule drug. Regulatory agencies, including the MHRA, require biosimilar applicants to run dedicated clinical comparability studies rather than simply matching a chemical fingerprint.

This process takes years and significant investment. Even after approval, a biosimilar needs to be manufactured at scale, packaged in a suitable delivery device (Wegovy uses a pre-filled auto-injector pen) and distributed through the licensed UK supply chain. Subcutaneous injection devices are themselves subject to separate regulatory requirements. None of this is insurmountable, but it means that even an optimistic post-exclusivity timeline for a semaglutide biosimilar reaching UK patients involves meaningful lead time after the first patent expires.

Tirzepatide, the dual GIP and GLP-1 receptor agonist sold as Mounjaro, operates under its own separate patent estate held by Eli Lilly. The weight-loss treatment landscape therefore includes medicines at very different stages of exclusivity, which matters if long-term cost trends are part of your planning.

What exclusivity expiry has historically done to medicine prices

The optimistic reading of Wegovy loss of exclusivity is that competition eventually drives prices down significantly, as it did with statins and many blood-pressure medicines. The cautious reading is that biologics and complex injectables tend to see more modest and slower price reductions than small-molecule generics, because biosimilar manufacturing costs remain high and the market is smaller. Evidence from other GLP-1 medicines globally suggests some price compression after exclusivity loss, but the degree varies substantially by country, payer system and the number of biosimilar entrants.

In the UK private market, current Wegovy pricing reflects originator costs, clinical infrastructure, dispensing and delivery. Any future price shift would depend on MHRA-approved biosimilars reaching market, which requires time to work through the approval and supply chain stages described above. It is also worth noting that Eli Lilly's decision to raise Mounjaro's list price substantially in September 2025 shows that originator prices can move in either direction, patent protection does not fix pricing. For the MHRA's published information on how GLP-1 medicines are regulated and monitored, the Yellow Card scheme remains the central reporting and monitoring mechanism, and the MHRA's public guidance on these medicines is updated as new evidence emerges.

Your prescription, and the prescriber who issues it, remain the constant regardless of which manufacturer's product sits in the fridge door. That clinical relationship (reviewing whether treatment is still appropriate, whether a dose change is warranted, whether side effects need attention) is what legitimises any GLP-1 supply chain, now and after any future exclusivity change. A question our prescribers hear regularly is whether people should wait for cheaper alternatives before starting. The honest clinical answer is that, for most people, time without appropriate treatment has its own costs.

What this means in practice if you are currently taking Wegovy or considering it

For people already prescribed Wegovy, nothing changes immediately. The Novo Nordisk product remains the only MHRA-licensed semaglutide preparation for weight management in the UK, and if you are interested in how the medicine achieves its results, our page on semaglutide fat loss explains the underlying mechanisms in detail, across both the established injection and the newer oral semaglutide tablet approved in June 2026. NICE's appraisal of semaglutide for weight management, published as NICE TA875, remains the clinical evidence base for prescribing decisions, and it was produced on data from the originator medicine. A future biosimilar would need to demonstrate comparable efficacy and safety before any clinical guideline could support substitution.

If you are weighing up whether to start treatment now or wait, a prescriber is the right person to work through that with you. They can assess which medicine fits your clinical picture, consider what the current evidence says about results and tolerability, including less commonly discussed effects such as the changes in smell sensitivity some people report, and explain how ongoing monitoring works. The semaglutide patent timeline is a reasonable thing to be curious about; it is not, on its own, a clinical reason to delay treatment that might benefit you. Speak to our prescribers through a free consultation to explore whether Wegovy or another licensed treatment is right for you now.